Clinical trials: Steroid Refractory
Frequent Relapsing Nephrotic Syndrome, Steroid Dependent Nephrotic Syndrome
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective than MMF in maintaining remission in children with frequent relapsing or steroid dependent nephrotic syndrome who have had one relapse while…
- Trial name
- RAMP (NCT02390362)
- Testing
- Rituximab, MMF
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Nationwide Children's Hospital
Pneumonia, Pneumocystis Carinii, HIV Infections
Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients
This study compares three different therapies for treatment of refractory Pneumocystis carinii pneumonia (PCP) in patients with AIDS.
- Trial name
- NCT00000730
- Testing
- Trimetrexate glucuronate, Methylprednisolone, Pentamidine isethionate
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Graft vs Host Disease
A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and…
- Trial name
- NCT03474679
- Testing
- Ibrutinib
- Where
- 15 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Pharmaceutical K.K.
Graft-versus-host Disease (GVHD)
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
To provide ruxolitinib through an expanded access to treat a single patient with cGVHD
- Trial name
- NCT05722912
- Testing
- Ruxolitinib
- Sponsor
- Incyte Corporation
Chronic Graft vs Host Disease
A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants
The purpose of this study is to evaluate the effectiveness of ibrutinib compared to conventional salvage treatments in participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall…
- Trial name
- NCT04852692
- Where
- 8 sites in South Korea
- Volunteers
- 15 people
- Sponsor
- Janssen Korea, Ltd., Korea
Lumbar Discogenic Pain (Disorder)
Ethanol Gel Versus Steroid in Refractory Lumbar Discogenic Pain
DISCOGEL® is on the market since 2007. About 20,000 kits were sold to date (October 2017). The device re-obtained its CE mark in 2017. A clinical evaluation was performed by bibliographic route in 2016.
- Trial name
- IDIS (NCT03415828)
- Testing
- Ethanol gel, Prednisolone acetate
- Where
- 5 sites in France
- Volunteers
- 230 people
- Sponsor
- Gelscom SAS
Graft-versus-Host Disease
A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Jakavi® (ruxolitinib) in the real-world clinical setting in Korean Graft-versus-Host disease (GvHD)…
- Trial name
- NCT05621733
- Testing
- ruxolitinib
- Where
- 14 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Graft-versus-host-disease
Anlotinib Treatment in Steroid Depenent/Refractory cGVHD
This is a single center, single arm, prospective, phase II clinical study. The main purpose of this study is to evaluate the efficacy and safety of anlotinib in the treatment of steroid dependent/refractory chronic…
- Trial name
- NCT04232397
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
This phase I trial tests the safety, side effects, and best dose of allogeneic CD6 chimeric antigen receptor T regulatory cells (CD6-CAR Tregs) in treating patients who have chronic graft versus host disease (cGVHD) after an…
- Conditions
- Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
- Trial name
- NCT05993611
- Testing
- Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Graft Versus Host Disease
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
This pilot clinical trial studies romidepsin in treating patients with graft-versus-host disease (GVHD) that has not responded to treatment with steroids.
- Trial name
- NCT02203578
- Testing
- romidepsin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rutgers, The State University of New Jersey
Steroid-Refractory Acute Graft Versus Host Disease
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)
The study is designed as an open-label, single arm Phase III, multicenter trial to evaluate the efficacy and safety of T-Guard treatment in patients with Steroid-Refractory acute Graft versus Host Disease (SR-aGVHD).
- Trial name
- 1802 (NCT04128319)
- Testing
- T-Guard
- Where
- 24 sites in United States
- Volunteers
- 3 people
- Sponsor
- Xenikos
Chronic Graft Versus Host Disease
Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease
This phase II trial studies efficacy of extracorporeal photopheresis and low dose aldesleukin (interleukin-2) in treating patients with chronic graft-versus-host disease (cGVHD) that does not respond to upfront treatment with…
- Trial name
- NCT03007238
- Testing
- Aldesleukin, Extracorporeal Photopheresis, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
PRIMARY OBJECTIVES: Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD. SECONDARY OBJECTIVES: Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.
- Conditions
- Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral
- Trial name
- NCT01155817
- Testing
- Nilotinib
- Where
- 5 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- Stanford University
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
- Trial name
- NCT03112603
- Testing
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX)
- Where
- 191 sites in United States, Australia and 29 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Graft vs Host Disease
A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease
Phase 1/2 clinical study for the treatment of steroid-refractory chronic graft versus host disease after an allogeneic transplant of hematopoietic progenitors with donor CliniMACS-selected regulatory T cells
- Trial name
- TREGeneration (NCT02385019)
- Testing
- Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease
- Where
- 3 sites in Portugal
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Instituto de Medicina Molecular João Lobo Antunes
Steroid Resistant Acute Graft Versus Host Disease
Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease
Leukotac (inolimomab) is not approved yet for marketing in any region. In the absence of medical options and based on the safety and efficacy data obtained during the clinical development program (in a phase III (INO-107) and in…
- Trial name
- NCT05047328
- Testing
- inolimomab
- Where
- France
- Sponsor
- ElsaLys Biotech
Chronic Graft-versus-host-disease
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
This research study is evaluating a combination of a therapy called Extra-corporeal Photopheresis (ECP) with a drug called Interleukin-2 (IL-2) as a possible treatment for chronic graft-versus-host-disease (GVHD) following…
- Trial name
- NCT02340676
- Testing
- Extracorporeal Photopheresis (ECP), Interleukin-2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Immune Thrombocytopenia
The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Single-arm, open-lable, multicentre study to compare the efficacy and safety of atorvastatin, acetylcysteine plus danazol with danazol monotherapy in patients with corticosteroidresistant/relapsed ITP.
- Trial name
- NCT03460808
- Testing
- atorvastatin, Acetylcysteine, Danazol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Graft-versus-Host Disease
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
The purpose of this research study is to test the safety and effectiveness of VELCADE® in the treatment of acute graft-versus-host disease (GVHD) that has not responded to steroids or has worsened when the steroid dose was…
- Trial name
- NCT00408928
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University